Table 1 The baseline characteristics of the included studies

Northeastern Ethiopia

Baye et al, 2018 [20]

2012–2016

RC

Pulmonary tuberculosis (96.5%)

Extra-pulmonary tuberculosis (3.5%)

Line probe assay

Culture

Xpert MTB/RIF

New (8.5%)

Relapse (13.5%)

After lost to follow up (2.1%)

Failure of a new regimen (30.5%)

After the failure of retreatment (42.6%)

Transfer in from other sites (1.4%)

Other (1.4%)

HIV co-infected, 38 (27%), the majority of the patients have received ART (84.2%)

Southern Ethiopia

Girum et al, 2017 [21]

2009 to 2014

RC

Pulmonary tuberculosis (94%)

Extra-pulmonary tuberculosis (6%)

Culture

Xpert MTB/RIF

History of previous treatment (90%)

New cases (10%)

HIV co-infection, 11 (7.2%), of them 9 have had a history of previous treatment

Northwest Ethiopia

Alene et al, 2017 [22]

2010 to 2015

RC

Pulmonary tuberculosis (94%)

Extra-pulmonary tuberculosis (6%)

Culture

Xpert MTB/RIF

History of previous treatment (93%)

New cases (7%)

HIV co-infection, 51 (21.1%)

Central Ethiopia

Mequanint et al., 2014 [23]

2011 to 2013

DRC

Pulmonary tuberculosis (84%)

Extra-pulmonary (15.6%)

Both, 0.4%

Culture

History of previous treatment, 35%

HIV co-infection, 193 (28.4%)

Eastern Ethiopia

Tolera et al. 2018 [24]

2005 to 2016

DRC

Pulmonary tuberculosis (98.2%)

Extra-pulmonary tuberculosis (1.8%)

–

Retreated cases, 97%

HIV co-infection, 41 (25%), the majority of the patients have received ART (97.6%)

Central and Northwest Ethiopia

Meressa et al., 2015 [25]

2009 to 2014

PC

Pulmonary tuberculosis (93%)

Extra-pulmonary tuberculosis (7%)

Culture

Line probe assay

History of previous treatment (98.5%)

HIV infection (21.7%)

HIV co-infection, 133 (21.7%), the median CD4 count was 239 cells/ml³, the majority of the patients have received ART (90.2%)